Kairos Pharma

Executive Summary

Kairos Pharma is a clinical-stage biopharmaceutical company developing novel therapies to overcome cancer drug resistance and tumor-induced immune suppression. Founded in 2018 and based in Cambridge, USA, the company's platform targets CD105 (endoglin), a protein implicated in resistance to multiple standard-of-care oncology agents. Its lead candidate, ENV105, is a monoclonal antibody designed to restore sensitivity to chemotherapy and targeted therapies by disrupting CD105-mediated signaling. The company is currently advancing ENV105 through Phase 2 clinical trials, with a focus on solid tumors where resistance remains a major unmet need. By addressing a core mechanism of treatment failure, Kairos Pharma aims to improve outcomes for patients who have progressed on existing therapies. Kairos Pharma operates in the competitive oncology landscape, but its differentiated approach targeting CD105 could position it for strategic partnerships or licensing deals with larger pharmaceutical companies. The private company has not disclosed total funding or valuation, but its progress to Phase 2 suggests meaningful investor support. Near-term success hinges on generating positive clinical data demonstrating ENV105's ability to reverse resistance and improve efficacy when combined with standard therapies. If successful, Kairos Pharma could offer a novel adjunctive treatment for multiple cancer types, potentially expanding the addressable market beyond current resistant subsets. The company's future value will depend on execution of its clinical roadmap and ability to attract commercial partners.

Upcoming Catalysts (preview)

• Q3 2026ENV105 Phase 2 interim data readout50% success
• Q2 2026Series B or C financing round60% success
• H2 2026Potential partnering or licensing deal for ENV10540% success